Evotec Results Presentation Deck

in € m¹) evotec Revenues from contracts with customers Gross margin Strong growth & investments into capacity, R&D, and SG&A Condensed income statement H1 2021 – Evotec SE and subsidiaries R&D expenses • SG&A expenses • Impairment of intangible assets and goodwill • Other op. income (expenses), net Operating result Adjusted Group EBITDA²) Net income PAGE 9 H1 2021 271.3 20.8% (35.4) (46.4) (0.7) 34.5 8.3 36.2 112.7 H1 2020 231.0 23.0% (29.8) (36.5) 32.2 18.9 47.3 7.3 Change 17% 19% 27% 7% (56)% (23)% >>>100% • Revenue growth 17% (27%, adjusted for portfolio & fx effects) • R&D expenses up 19% as planned • SG&A up 27% as planned due to upscaling and depreciation, plus final ramp-up J.PODⓇ 1 US ahead of opening Adj. EBITDA like-for-like growth 13% despite higher R&D and SG&A • Net income benefits from fair value adjustment of EVO equity investment Exscientia ¹) Differences may occur due to rounding 2) Before contingent considerations, income from bargain purchase and excl. impairments on goodwill, other intangible and tangible assets as well as the total non-operating result 3) Sanofi payment Q1 2020

View entire presentation